AI in Clinical Trials Market Report and Forecast 2025-2034
Description
The global AI in clinical trials market was valued at USD 2.05 Billion in 2024, driven by rising requirements to overcome data limitations across the globe. It is expected to grow at a CAGR of 14.00% during the forecast period 2025-2034, and attain a market value of USD 7.60 Billion by 2034.
AI in Clinical Trials Market Overview
AI technology, combined with big data, can tackle major obstacles in clinical trials by processing and examining large volumes of data. AI and advanced analytics can enhance productivity in clinical R&D by merging trial phases, developing patient-focused endpoints, and examining real world data. Increased participation of AI in drug research and development is expected to fuel market growth. Additionally, the market is impacted by the increasing emphasis on diversity and inclusivity.
AI in Clinical Trials Market Growth Drivers
Artificial Intelligence (AI) in Drug Research and Development to Drive Market Growth
Advancements in technology and artificial intelligence are driving growth in the field of drug research and development. A July 2024 update demonstrates how AI and data analytics are reducing time and costs for introducing medications to the market, improving efficiency in clinical trials, managing data complexities, and optimizing technological investments in the biopharmaceutical industry.
AI in Clinical Trials Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Focus on Diversity and Inclusivity
Emphasizing diversity and inclusivity is a significant market trend. A study published in October 2024 revealed that 80% of clinical trials encounter challenges in recruiting diverse participants. AI can help address these challenges by improving engagement and inclusivity in clinical trials.
Increasing Collaboration and Partnership
A noteworthy trend in the market is the growing partnership and collaboration among companies. In October 2024, Eli Lilly partnered with Insitro in the AI-driven clinical trials sector. Under this partnership, Insitro will focus on drug discovery, bringing new treatments to market, and will pay royalties to Lilly, signaling a trend towards biotech collaboration and trust in AI firms.
Growing Focus on Overcoming Data Limitations
The use of generative AI in clinical trials, especially for diseases such as acute myeloid leukemia, is a significant trend in the market. Research published in March 2024 on utilizing generative AI for producing artificial patient information for this illness shows increasing possibilities in the AI within the clinical trials market and encouraging broader utilization of AI in clinical trials, resulting in market growth.
Focus on Patient Outcomes and Accessibility
The market is witnessing a trend of increased focus on enhancing patient results and expanding access to advanced treatments by turning clinics into innovation hubs. This is in line with larger patterns in the healthcare industry that focus on putting patients first and providing individualized medical treatments.
AI in Clinical Trials Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Phase:
Market Segmentation Based on the Application to Witness Growth
Based on the application, the market for AI in clinical trials is segmented into oncology, neurology diseases, cardiological diseases, infectious diseases, immunological diseases, and others. The infectious disease segment is expected to dominate the market share as AI allows for the effective processing and analysis of complex data sets, helping researchers gain new insights and make defensible conclusions in clinical studies.
AI in Clinical Trials Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America, especially the United States, is at the forefront of AI innovation and technology, leading the AI in clinical trials market. This dominance is driven by the presence of major IT companies, educational institutions, and new startups dedicated to developing and advancing AI technologies for various sectors.
Leading Players in the AI in Clinical Trials Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Unlearn.ai, Inc.
Unlearn.AI is a healthcare AI company that develops AI to speed up drug development and remove trial and error in medicine using digital twins.
Saama
Saama, is a consulting and systems integration firma platform for clinical analytics powered by AI, presents GenAI and collaborative tools to improve data analysis in clinical development.
Antidote Technologies, Inc.
Antidote is a digital health company that employs artificial intelligence and digital technologies to improve the recruitment of participants for clinical trials, helping medical research by effectively linking patients with trials, thereby decreasing delays and expenses and ultimately benefiting the global AI in clinical trials market.
Phesi
Phesi, a United States-based company specializing in data infrastructure and analytics for clinical trials, provides AI-based data solutions through their trial accelerator™ platform to enhance trial results for pharmaceutical and biotech firms.
Other key players in the market include Deep6.ai, Innoplexus, Intelligencia AI, Median Technologies, and Consilx.
Key Questions Answered in the AI in Clinical Trials Market Report
AI in Clinical Trials Market Overview
AI technology, combined with big data, can tackle major obstacles in clinical trials by processing and examining large volumes of data. AI and advanced analytics can enhance productivity in clinical R&D by merging trial phases, developing patient-focused endpoints, and examining real world data. Increased participation of AI in drug research and development is expected to fuel market growth. Additionally, the market is impacted by the increasing emphasis on diversity and inclusivity.
AI in Clinical Trials Market Growth Drivers
Artificial Intelligence (AI) in Drug Research and Development to Drive Market Growth
Advancements in technology and artificial intelligence are driving growth in the field of drug research and development. A July 2024 update demonstrates how AI and data analytics are reducing time and costs for introducing medications to the market, improving efficiency in clinical trials, managing data complexities, and optimizing technological investments in the biopharmaceutical industry.
AI in Clinical Trials Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Focus on Diversity and Inclusivity
Emphasizing diversity and inclusivity is a significant market trend. A study published in October 2024 revealed that 80% of clinical trials encounter challenges in recruiting diverse participants. AI can help address these challenges by improving engagement and inclusivity in clinical trials.
Increasing Collaboration and Partnership
A noteworthy trend in the market is the growing partnership and collaboration among companies. In October 2024, Eli Lilly partnered with Insitro in the AI-driven clinical trials sector. Under this partnership, Insitro will focus on drug discovery, bringing new treatments to market, and will pay royalties to Lilly, signaling a trend towards biotech collaboration and trust in AI firms.
Growing Focus on Overcoming Data Limitations
The use of generative AI in clinical trials, especially for diseases such as acute myeloid leukemia, is a significant trend in the market. Research published in March 2024 on utilizing generative AI for producing artificial patient information for this illness shows increasing possibilities in the AI within the clinical trials market and encouraging broader utilization of AI in clinical trials, resulting in market growth.
Focus on Patient Outcomes and Accessibility
The market is witnessing a trend of increased focus on enhancing patient results and expanding access to advanced treatments by turning clinics into innovation hubs. This is in line with larger patterns in the healthcare industry that focus on putting patients first and providing individualized medical treatments.
AI in Clinical Trials Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Phase:
- Phase I
- Phase II
- Phase III
- Oncology
- Neurology Diseases
- Cardiological Diseases
- Infectious Disease
- Immunological Diseases
- Others
- Pharmaceutical and Biopharmaceutical Companies
- Academic and Research Institutes
- Cancer Centers
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Segmentation Based on the Application to Witness Growth
Based on the application, the market for AI in clinical trials is segmented into oncology, neurology diseases, cardiological diseases, infectious diseases, immunological diseases, and others. The infectious disease segment is expected to dominate the market share as AI allows for the effective processing and analysis of complex data sets, helping researchers gain new insights and make defensible conclusions in clinical studies.
AI in Clinical Trials Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America, especially the United States, is at the forefront of AI innovation and technology, leading the AI in clinical trials market. This dominance is driven by the presence of major IT companies, educational institutions, and new startups dedicated to developing and advancing AI technologies for various sectors.
Leading Players in the AI in Clinical Trials Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Unlearn.ai, Inc.
Unlearn.AI is a healthcare AI company that develops AI to speed up drug development and remove trial and error in medicine using digital twins.
Saama
Saama, is a consulting and systems integration firma platform for clinical analytics powered by AI, presents GenAI and collaborative tools to improve data analysis in clinical development.
Antidote Technologies, Inc.
Antidote is a digital health company that employs artificial intelligence and digital technologies to improve the recruitment of participants for clinical trials, helping medical research by effectively linking patients with trials, thereby decreasing delays and expenses and ultimately benefiting the global AI in clinical trials market.
Phesi
Phesi, a United States-based company specializing in data infrastructure and analytics for clinical trials, provides AI-based data solutions through their trial accelerator™ platform to enhance trial results for pharmaceutical and biotech firms.
Other key players in the market include Deep6.ai, Innoplexus, Intelligencia AI, Median Technologies, and Consilx.
Key Questions Answered in the AI in Clinical Trials Market Report
- What was the AI in clinical trials market value in 2024?
- What is the AI in clinical trials market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on application?
- What is the market segmentation based on phase?
- What is the market breakup based on the end user?
- What are the major factors aiding the AI in clinical trials market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the AI in clinical trials market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global AI in Clinical Trials Market Overview
- 3.1 Global AI in Clinical Trials Market Historical Value 2018-2024
- 3.2 Global AI in Clinical Trials Market Forecast Value 2025-2034
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global AI in Clinical Trials Market Landscape*
- 5.1 Global AI in Clinical Trials Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global AI in Clinical Trials Market: Product Landscape
- 5.2.1 Analysis by Phase
- 5.2.2 Analysis by Application
- 6 Global AI in Clinical Trials Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global AI in Clinical Trials Market Segmentation 218-2034
- 7.1 Global AI in Clinical Trials Market 2018-2034 by Phase
- 7.1.1 Market Overview
- 7.1.2 Phase I
- 7.1.3 Phase II
- 7.1.4 Phase III
- 7.2 Global AI in Clinical Trials Market 2018-2034 by Application
- 7.2.1 Market Overview
- 7.2.2 Oncology
- 7.2.3 Neurology Diseases
- 7.2.4 Cardiological Diseases
- 7.2.5 Infectious Disease
- 7.2.6 Immunological Diseases
- 7.2.7 Others
- 7.3 Global AI in Clinical Trials Market 2018-2034 by End User
- 7.3.1 Market Overview
- 7.3.2 Pharmaceutical and Biopharmaceutical Companies
- 7.3.3 Academic and Research Institutes
- 7.3.4 Cancer Centers
- 7.3.5 Others
- 7.4 Global AI in Clinical Trials Market 2018-2034 by Region
- 7.4.1 Market Overview
- 7.4.2 North America
- 7.4.3 Europe
- 7.4.4 Asia Pacific
- 7.4.5 Latin America
- 7.4.6 Middle East and Africa
- 8 North America AI in Clinical Trials Market 218-2034
- 8.1 North America AI in Clinical Trials Market 2018-2034 by Phase
- 8.1.1 Market Overview
- 8.1.2 Phase I
- 8.1.3 Phase II
- 8.1.4 Phase III
- 8.2 North America AI in Clinical Trials Market 2018-2034 by Application
- 8.2.1 Market Overview
- 8.2.2 Oncology
- 8.2.3 Neurology Diseases
- 8.2.4 Cardiological Diseases
- 8.2.5 Infectious Disease
- 8.2.6 Immunological Diseases
- 8.2.7 Others
- 8.3 North America AI in Clinical Trials Market 2018-2034 by End User
- 8.3.1 Market Overview
- 8.3.2 Pharmaceutical and Biopharmaceutical Companies
- 8.3.3 Academic and Research Institutes
- 8.3.4 Cancer Centers
- 8.3.5 Others
- 8.4 North America AI in Clinical Trials Market 2018-2034 by Country
- 8.4.1 United States of America
- 8.4.2 Canada
- 9 Europe AI in Clinical Trials Market 218-2034
- 9.1 Europe AI in Clinical Trials Market 2018-2034 by Phase
- 9.1.1 Market Overview
- 9.1.2 Phase I
- 9.1.3 Phase II
- 9.1.4 Phase III
- 9.2 Europe AI in Clinical Trials Market 2018-2034 by Application
- 9.2.1 Market Overview
- 9.2.2 Oncology
- 9.2.3 Neurology Diseases
- 9.2.4 Cardiological Diseases
- 9.2.5 Infectious Disease
- 9.2.6 Immunological Diseases
- 9.2.7 Others
- 9.3 Europe AI in Clinical Trials Market 2018-2034 by End User
- 9.3.1 Market Overview
- 9.3.2 Pharmaceutical and Biopharmaceutical Companies
- 9.3.3 Academic and Research Institutes
- 9.3.4 Cancer Centers
- 9.3.5 Others
- 9.4 Europe AI in Clinical Trials Market 2018-2034 by Country
- 9.4.1 United Kingdom
- 9.4.2 Germany
- 9.4.3 France
- 9.4.4 Italy
- 9.4.5 Others
- 10 Asia Pacific AI in Clinical Trials Market 218-2034
- 10.1 Asia Pacific AI in Clinical Trials Market 2018-2034 by Phase
- 10.1.1 Market Overview
- 10.1.2 Phase I
- 10.1.3 Phase II
- 10.1.4 Phase III
- 10.2 Asia Pacific AI in Clinical Trials Market 2018-2034 by Application
- 10.2.1 Market Overview
- 10.2.2 Oncology
- 10.2.3 Neurology Diseases
- 10.2.4 Cardiological Diseases
- 10.2.5 Infectious Disease
- 10.2.6 Immunological Diseases
- 10.2.7 Others
- 10.3 Asia Pacific AI in Clinical Trials Market 2018-2034 by End User
- 10.3.1 Market Overview
- 10.3.2 Pharmaceutical and Biopharmaceutical Companies
- 10.3.3 Academic and Research Institutes
- 10.3.4 Cancer Centers
- 10.3.5 Others
- 10.4 Asia Pacific AI in Clinical Trials Market 2018-2034 by Country
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 ASEAN
- 10.4.5 Australia
- 10.4.6 Others
- 11 Latin America AI in Clinical Trials Market 218-2034
- 11.1 Latin America AI in Clinical Trials Market 2018-2034 by Phase
- 11.1.1 Market Overview
- 11.1.2 Phase I
- 11.1.3 Phase II
- 11.1.4 Phase III
- 11.2 Latin America AI in Clinical Trials Market 2018-2034 by Application
- 11.2.1 Market Overview
- 11.2.2 Oncology
- 11.2.3 Neurology Diseases
- 11.2.4 Cardiological Diseases
- 11.2.5 Infectious Disease
- 11.2.6 Immunological Diseases
- 11.2.7 Others
- 11.3 Latin America AI in Clinical Trials Market 2018-2034 by End User
- 11.3.1 Market Overview
- 11.3.2 Pharmaceutical and Biopharmaceutical Companies
- 11.3.3 Academic and Research Institutes
- 11.3.4 Cancer Centers
- 11.3.5 Others
- 11.4 Latin America AI in Clinical Trials Market 2018-2034 by Country
- 11.4.1 Brazil
- 11.4.2 Argentina
- 11.4.3 Mexico
- 11.4.4 Others
- 12 Middle East and Africa AI in Clinical Trials Market 218-2034
- 12.1 Middle East and Africa AI in Clinical Trials Market 2018-2034 by Phase
- 12.1.1 Market Overview
- 12.1.2 Phase I
- 12.1.3 Phase II
- 12.1.4 Phase III
- 12.2 Middle East and Africa AI in Clinical Trials Market 2018-2034 by Application
- 12.2.1 Market Overview
- 12.2.2 Oncology
- 12.2.3 Neurology Diseases
- 12.2.4 Cardiological Diseases
- 12.2.5 Infectious Disease
- 12.2.6 Immunological Diseases
- 12.2.7 Others
- 12.3 Middle East and Africa AI in Clinical Trials Market 2018-2034 by End User
- 12.3.1 Market Overview
- 12.3.2 Pharmaceutical and Biopharmaceutical Companies
- 12.3.3 Academic and Research Institutes
- 12.3.4 Cancer Centers
- 12.3.5 Others
- 12.4 Middle East and Africa AI in Clinical Trials Market 2018-2034 by Country
- 12.4.1 Saudi Arabia
- 12.4.2 United Arab Emirates
- 12.4.3 Nigeria
- 12.4.4 South Africa
- 12.4.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Drug Class of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Strategic Initiatives
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Drug Class of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share Analysis, By Region (Top 5 Companies)
- 17.1.1 Market Share Analysis: Global
- 17.1.2 Market Share Analysis: North America
- 17.1.3 Market Share Analysis: Europe
- 17.1.4 Market Share Analysis: Asia Pacific
- 17.1.5 Market Share Analysis: Others
- 17.2 Unlearn.ai, Inc.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Company News and Development
- 17.2.5 Certifications
- 17.3 Saama
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Company News and Development
- 17.3.5 Certifications
- 17.4 Antidote Technologies, Inc.
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Company News and Development
- 17.4.5 Certifications
- 17.5 Phesi
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Company News and Development
- 17.5.5 Certifications
- 17.6 Deep6.ai
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Company News and Development
- 17.6.5 Certifications
- 17.7 Innoplexus
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Company News and Development
- 17.7.5 Certifications
- 17.8 Intelligencia AI
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Company News and Development
- 17.8.5 Certifications
- 17.9 Median Technologies
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Company News and Development
- 17.9.5 Certifications
- 17.10 Consilx
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Company News and Development
- 17.10.5 Certifications
- 18 Global AI in Clinical Trials Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
